Trial Profile
A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Recurrent Malignant Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Toripalimab (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
- 28 Sep 2020 Status changed from active, no longer recruiting to completed.
- 07 Mar 2019 Planned End Date changed from 30 Oct 2018 to 30 Dec 2019.
- 04 Sep 2018 Planned End Date changed from 30 Jun 2018 to 30 Oct 2018.